{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:06:15Z","timestamp":1790186775752,"version":"4.1.0"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2013,3,6]],"date-time":"2013-03-06T00:00:00Z","timestamp":1362528000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0057854","type":"journal-article","created":{"date-parts":[[2013,3,6]],"date-time":"2013-03-06T20:47:43Z","timestamp":1362602863000},"page":"e57854","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":36,"title":["The Effects of Calcium Channel Blockers in the Prevention of Stroke in Adults with Hypertension: A Meta-Analysis of Data from 273,543 Participants in 31 Randomized Controlled Trials"],"prefix":"10.1371","volume":"8","author":[{"given":"Gui Jv","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao Sheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,3,6]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(64)92344-X","article-title":"The role of blood-pressure control in preventing complications of hypertension","volume":"1","author":"M Hamilton","year":"1964","journal-title":"Lancet"},{"key":"ref2","first-page":"10","article-title":"Long-term calcium channel blockers: The best choice of antihypertensive treatment for the Chinese hypertensive population","volume":"13","author":"GT Liu","year":"2011","journal-title":"Zhongguo She Qu Yi Shi"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/01.HYP.34.5.1129","article-title":"Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives","volume":"34","year":"1999","journal-title":"Hypertension"},{"key":"ref4","first-page":"4039","article-title":"Antihypertensive effect of levamlodipine besylate and enalapril in the patients with cerebrovascular disorder","volume":"31","author":"YY Song","year":"2011","journal-title":"Zhongguo Lao Nian Xue Za Zhi"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(00)02526-5","article-title":"Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study","volume":"356","author":"L Hansson","year":"2000","journal-title":"Lancet"},{"key":"ref6","first-page":"107","article-title":"Reflections on controlled trial","volume":"25","author":"AB Hill","year":"1966","journal-title":"Ann Rheum Dis"},{"key":"ref7","first-page":"295","article-title":"The Environment and Disease: Association or Causation?","volume":"58","author":"AB Hill","year":"1965","journal-title":"Proc R Soc Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"M Egger","year":"1997","journal-title":"BMJ"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/oxfordjournals.aje.a117644","article-title":"Heterogeneity in meta-analysis of data from epidemiologic studies: a commentary","volume":"142","author":"GA Colditz","year":"1995","journal-title":"Am J Epidemiol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"JP Higgins","year":"2002","journal-title":"Stat Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/bmj.323.7305.157","article-title":"Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests","volume":"323","author":"JJ Deeks","year":"2001","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(97)05381-6","article-title":"Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators","volume":"350","author":"JA Staessen","year":"1997","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2337\/diacare.21.4.597","article-title":"Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM","volume":"21","author":"P Tatti","year":"1998","journal-title":"Diabetes Care"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/01.hjh.0000160223.94220.29","article-title":"ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators.Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial","volume":"23","author":"J Lubsen","year":"2005","journal-title":"J Hypertens"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/00004872-199816120-00016","article-title":"Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group","volume":"16","author":"L Liu","year":"1998","journal-title":"J Hypertens"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(04)16980-8","article-title":"Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial","volume":"364","author":"PA Poole-Wilson","year":"2004","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1474-4422(10)70066-1","article-title":"ASCOT-BPLA and MRC Trial Investigators. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke","volume":"9","author":"PM Rothwell","year":"2010","journal-title":"Lancet Neurol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/08037050410014944","article-title":"Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2","volume":"13","author":"T Ekbom","year":"2004","journal-title":"Blood Press"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","article-title":"ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial","volume":"366","author":"B Dahl\u00f6f","year":"2005","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1161\/01.HYP.0000231662.77359.de","article-title":"Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial","volume":"48","author":"FH Leenen","year":"2006","journal-title":"Hypertension"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1097\/01.hjh.0000194120.42722.ac","article-title":"FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients","volume":"23","author":"L Liu","year":"2005","journal-title":"J Hypertens"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1161\/01.CIR.0000039288.86470.DD","article-title":"European Lacidipine Study on Atherosclerosis investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial","volume":"106","author":"A Zanchetti","year":"2002","journal-title":"Circulation"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","article-title":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials","volume":"362","author":"F Turnbull","year":"2003","journal-title":"Lancet"},{"key":"ref24","first-page":"235","article-title":"Effect of calcium antagonists on the secondary prevention of essential hypertension","volume":"6","author":"YZ Wang","year":"1998","journal-title":"Zhongguo Man Xing Bing Yu Fang Yu Kong Zhi"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0002-9149(00)01267-4","article-title":"Usefulness of Nisoldipine for prevention of restenosis after percutaneous transluminal coronary angioplasty (results of the NICOLE study). Nisoldipine in Coronary artery disease in Leuven","volume":"87","author":"JA Dens","year":"2001","journal-title":"Am J Cardiol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/00004872-199610000-00013","article-title":"Shanghai trial of nifedipine in the elderly (STONE)","volume":"14","author":"L Gong","year":"1996","journal-title":"J Hypertens"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1001\/jama.289.16.2073","article-title":"CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial","volume":"289","author":"HR Black","year":"2003","journal-title":"JAMA"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","article-title":"Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study","volume":"354","author":"L Hansson","year":"1999","journal-title":"Lancet"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0140-6736(00)02527-7","article-title":"Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)","volume":"356","author":"MJ Brown","year":"2000","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","article-title":"INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial","volume":"290","author":"CJ Pepine","year":"2003","journal-title":"JAMA"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.1996.03540100029024","article-title":"Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial","volume":"276","author":"NO Borhani","year":"1996","journal-title":"JAMA"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/08037050310009545","article-title":"Shell Investigators. Treatment of isolated systolic hypertension: the SHELL study results","volume":"12","author":"E Malacco","year":"2003","journal-title":"Blood Press"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1097\/00004872-199816110-00014","article-title":"The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness","volume":"16","author":"A Zanchetti","year":"1998","journal-title":"J Hypertens"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM199803053381003","article-title":"The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension","volume":"338","author":"RO Estacio","year":"1998","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1291\/hypres.26.979","article-title":"CASE-J Study Group. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods","volume":"26","author":"T Fukui","year":"2003","journal-title":"Hypertens Res"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/0003-4819-138-7-200304010-00010","article-title":"Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy","volume":"138","author":"T Berl","year":"2003","journal-title":"Ann Intern Med"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM199903043400902","article-title":"Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators","volume":"340","author":"J Tuomilehto","year":"1999","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/01.STR.0000166048.35740.a9","article-title":"MOSES Study Group. Morbidity and Mortality after Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES)","volume":"36","author":"J Schrader","year":"2005","journal-title":"Stroke"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/ACO.0b013e32835721a5","article-title":"Blood pressure management in stroke","volume":"25","author":"AL Donovan","year":"2012","journal-title":"Curr Opin Anaesthesiol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0057854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T19:27:58Z","timestamp":1540322878000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0057854"}},"subtitle":[],"editor":[{"given":"James M.","family":"Wright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,3,6]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,3,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0057854","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,6]]}}}